Molecular biologist Joe Cohen, one of the inventors and original patent-holder of the RTS,S/AS02A malaria vaccine, is hoping for an effective malaria vaccine by 2015. He is Vice President, R&D Emerging Diseases and HIV, at GlaxoSmithKline. On 18th October he announced the first-ever Phase III trial of the vaccine, which prevented clinical malaria in 56% of five months to 17-month-old babies – and prevented severe malaria in 47% of cases after three doses.
Estimated Reading Time - Less than 1 min.
Previous article
Next article